Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine–phenotype study
暂无分享,去创建一个
A. Tefferi | A. Pardanani | C. Hanson | C. Finke | T. Lasho | C. Finke | R. Abdelrahman
[1] J. Cerhan,et al. Elevated pretreatment serum levels of interferon‐inducible protein‐10 (CXCL10) predict disease relapse and prognosis in diffuse large B‐cell lymphoma patients , 2012, American journal of hematology.
[2] A. Órfão,et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis , 2012, Leukemia.
[3] A. Órfão,et al. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion , 2012, Modern Pathology.
[4] A. Tefferi,et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes , 2011, Leukemia.
[5] S. Ansell,et al. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. , 2011, Blood.
[6] A. Tefferi,et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Tefferi,et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. , 2010, Blood.
[8] A. Órfão,et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. , 2009, The Journal of allergy and clinical immunology.
[9] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[10] A. Tefferi,et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.
[11] A. Kasprzak,et al. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review. , 2008, Medical science monitor : international medical journal of experimental and clinical research.
[12] K. Sotlar,et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge , 2004, Journal of Clinical Pathology.
[13] L. Scott,et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. , 2000, Blood.